Rallybio RLYB
NASDAQ RLYB
$16.32 -0.06 (-0.40%)
As of: Oct 21, 2026 · 3:59 PM EDT

Rallybio (RLYB) Current Deferred Revenue (2024 - 2025)

Updated

Rallybio's Current Deferred Revenue came in at $212,000 for Q4 2025, down 75.0% from $848,000 a year earlier and down 50.0% from the prior quarter.

Analysis

Rallybio (RLYB) Current Deferred Revenue (2024 - 2025) Analysis & Trends

Going back to Q2 2024, Rallybio's Current Deferred Revenue data covers 7 quarters.

  • Going back by year, Current Deferred Revenue was $848,000 in FY2024.
  • Year-over-year, Current Deferred Revenue has declined for three consecutive quarters.
  • Business Quant data shows RLYB's Current Deferred Revenue at $424,000 (Q3 2025), $636,000 (Q2 2025) and $848,000 (Q1 2025) in the three quarters before Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Rallybio 92.10 Mn -161.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 212,000.00
Sep 30, 2025 424,000.00
Jun 30, 2025 636,000.00
Mar 31, 2025 848,000.00
Dec 31, 2024 848,000.00
Sep 30, 2024 1.10 Mn
Jun 30, 2024 1.20 Mn
API Access

Rallybio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RLYB&period=max&api_key=YOUR_API_KEY